HOUSTON–(BUSINESS WIRE)–Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion and certification of its GMP facility in Houston, Texas:

• GMP facility construction is complete and certified to meet all FDA required regulatory guidelines.
• GMP facility is ready to support our upcoming first in-human, off-the-shelf, allogenic CAR-T trial. The CAR-T ovarian cancer trials will have these targets: chPD1 Gamma-Delta and anti-ISOMSLN.
• Gamma-Delta-T cell (GDT cell) GMP manufacturing test batch optimization and qualification studies are proceeding as scheduled.

“The in-house capability to manufacture allogenic, off-the-shelf CAR products removes a layer of complexity in the workflow, which we believe will greatly enhance our ability to move swiftly through our CAR-T trials,” says Dr. Maurizio Chiriva-Internati, PhD, CEO of Kiromic BioPharma.

“The key features of the facility have been completed, clearing the path for the production of our off-the-shelf Gamma-Delta-T cells, a novel approach to CAR-T cell therapy, which will be evaluated in the upcoming clinical trials,” says David Aguilar, PhD, Head of CMC Manufacturing of Kiromic BioPharma.

“Thanks to the hard work of our scientists, contractor engineers, suppliers, and the third party certifiers, our Houston Facility is completing the final steps needed for launching the next-generation of allogenic, off-the-shelf CAR-T,” says Mr. Tony Tontat, CFO, COO of Kiromic BioPharma.

(chPD1: Chimeric PD1; ISOMSLN: Iso-mesothelin; CAR: Chimeric Antigen Receptors)

About Allogenic Gamma-Delta-T cells

GDT cells are a small fraction of blood lymphocytes, but they are the predominant T cell type in epithelia, where they patrol the barrier between the body and the outside world, with their potent multi-anti-pathogen abilities. (Read more…) Compared with alpha-beta-T cells (ABT), currently used in CAR therapies, GDT cells are more efficient in killing tumor cells and more resistant to mechanisms by which solid tumors escape from the immune system.

Furthermore, unlike ABT cells, GDT cells manufacturing does not require the patient’s blood, but can be produced using the blood of healthy donors, a process called allogenic cell transfer. This is possible because, while ABT cells from another individual will attack a patient’s normal organs, GDT cells will only target the tumor target for which they were engineered, leaving non-tumoral cells untouched.

The workflow of CAR-T therapy is as follows:

1. The GDT cells are grown and purified from the blood of healthy individuals.
2. The GDT cells are expanded with a proprietary process.
3. The GDT cells are then genetically modified to target tumor antigens discovered by Kiromic’s Diamond AI technology, resulting in the next generation of CAR-T cell therapy for solid malignancies.

About Kiromic

Kiromic BioPharma, Inc. is an immuno-oncology biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.” Kiromic’s DIAMOND is essentially big data science meeting target identification, dramatically compressing the man-years and the millions of drug development dollars needed to develop a live drug. The Company’s headquarters are located in Houston, TX adjacent to the world’s largest medical center and the MD Anderson Cancer Center.

For more information, please visit Kiromic’s website at:

www.kiromic.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about our intentions, projections, assessments, or expectations regarding items such as the following:

• our goals and strategies
• research, development, and regulatory activities
• FDA authorization timeline for clinical trial initiation
• clinical trial enrollment or participation by clinical sites
• facility manufacturing capabilities for clinical trial support
• expectations related to gamma delta CAR therapy
• performance and success of clinical trials
• our future business development, financial condition, and results of operations
• expected changes in our revenue, costs, or expenditures
• growth of and competition trends in our industry
• our expectations regarding demand for, and market acceptance of, our products
• our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with
• fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19
• relevant government policies and regulations relating to our industry.

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” included in our Registration Statement on Form S-1 (file no. 333-238153), originally filed with the Securities and Exchange Commission (SEC) on May 11, 2020, as amended, and elsewhere in this press release. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason. You are advised, however, to review any further disclosures we make on related subjects in our Forms 10-Q, 8-K and other reports filed with the SEC.

Contacts

Tony Tontat
Chief Financial Officer
(844) 539 – 2873

[email protected]

HOUSTON–(BUSINESS WIRE)–Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion and certification of its GMP facility in Houston, Texas:

• GMP facility construction is complete and certified to meet all FDA required regulatory guidelines.
• GMP facility is ready to support our upcoming first in-human, off-the-shelf, allogenic CAR-T trial. The CAR-T ovarian cancer trials will have these targets: chPD1 Gamma-Delta and anti-ISOMSLN.
• Gamma-Delta-T cell (GDT cell) GMP manufacturing test batch optimization and qualification studies are proceeding as scheduled.

“The in-house capability to manufacture allogenic, off-the-shelf CAR products removes a layer of complexity in the workflow, which we believe will greatly enhance our ability to move swiftly through our CAR-T trials,” says Dr. Maurizio Chiriva-Internati, PhD, CEO of Kiromic BioPharma.

“The key features of the facility have been completed, clearing the path for the production of our off-the-shelf Gamma-Delta-T cells, a novel approach to CAR-T cell therapy, which will be evaluated in the upcoming clinical trials,” says David Aguilar, PhD, Head of CMC Manufacturing of Kiromic BioPharma.

“Thanks to the hard work of our scientists, contractor engineers, suppliers, and the third party certifiers, our Houston Facility is completing the final steps needed for launching the next-generation of allogenic, off-the-shelf CAR-T,” says Mr. Tony Tontat, CFO, COO of Kiromic BioPharma.

(chPD1: Chimeric PD1; ISOMSLN: Iso-mesothelin; CAR: Chimeric Antigen Receptors)

About Allogenic Gamma-Delta-T cells

GDT cells are a small fraction of blood lymphocytes, but they are the predominant T cell type in epithelia, where they patrol the barrier between the body and the outside world, with their potent multi-anti-pathogen abilities. (Read more…) Compared with alpha-beta-T cells (ABT), currently used in CAR therapies, GDT cells are more efficient in killing tumor cells and more resistant to mechanisms by which solid tumors escape from the immune system.

Furthermore, unlike ABT cells, GDT cells manufacturing does not require the patient’s blood, but can be produced using the blood of healthy donors, a process called allogenic cell transfer. This is possible because, while ABT cells from another individual will attack a patient’s normal organs, GDT cells will only target the tumor target for which they were engineered, leaving non-tumoral cells untouched.

The workflow of CAR-T therapy is as follows:

1. The GDT cells are grown and purified from the blood of healthy individuals.
2. The GDT cells are expanded with a proprietary process.
3. The GDT cells are then genetically modified to target tumor antigens discovered by Kiromic’s Diamond AI technology, resulting in the next generation of CAR-T cell therapy for solid malignancies.

About Kiromic

Kiromic BioPharma, Inc. is an immuno-oncology biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.” Kiromic’s DIAMOND is essentially big data science meeting target identification, dramatically compressing the man-years and the millions of drug development dollars needed to develop a live drug. The Company’s headquarters are located in Houston, TX adjacent to the world’s largest medical center and the MD Anderson Cancer Center.

For more information, please visit Kiromic’s website at:

www.kiromic.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about our intentions, projections, assessments, or expectations regarding items such as the following:

• our goals and strategies
• research, development, and regulatory activities
• FDA authorization timeline for clinical trial initiation
• clinical trial enrollment or participation by clinical sites
• facility manufacturing capabilities for clinical trial support
• expectations related to gamma delta CAR therapy
• performance and success of clinical trials
• our future business development, financial condition, and results of operations
• expected changes in our revenue, costs, or expenditures
• growth of and competition trends in our industry
• our expectations regarding demand for, and market acceptance of, our products
• our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with
• fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19
• relevant government policies and regulations relating to our industry.

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” included in our Registration Statement on Form S-1 (file no. 333-238153), originally filed with the Securities and Exchange Commission (SEC) on May 11, 2020, as amended, and elsewhere in this press release. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason. You are advised, however, to review any further disclosures we make on related subjects in our Forms 10-Q, 8-K and other reports filed with the SEC.

Contacts

Tony Tontat
Chief Financial Officer
(844) 539 – 2873

[email protected]